Bank Of Montreal Stock Price, News & Analysis

BMO Financial Group (NYSE:BMO) has announced a dividend increase for the third quarter of fiscal year 2025. The quarterly dividend on common shares will be $1.63 per share, representing a 4 cent (3%) increase from the previous quarter and a 5% increase from the prior year. The dividend will be payable on August 26, 2025, to shareholders of record on July 30, 2025.

Additionally, BMO declared dividends on preferred shares: $0.190875 per share for Series 33 and $0.426 per share for Series 44, both payable on August 25, 2025. Shareholders can participate in the Dividend Reinvestment and Share Purchase Plan to reinvest their cash dividends in common shares, with purchases made on the open market without a discount.

BMO is set to host its 20th annual Farm to Market | Chemicals Conference on May 14-15, 2025, at the InterContinental Barclay Hotel in New York. The two-day event will bring together global institutional investors, financial sponsors, and companies from across the food, agriculture, and chemical sectors.

The conference will feature presentations and panel discussions on crucial industry topics, including alternative capital sources, consumer health trends, M&A markets, functional beverages, sustainability strategies, and the impact of GLP1+ therapeutics. BMO's leading analysts will lead discussions with over 100 major companies, including Archer-Daniels-Midland, Bayer, CF Industries, Kroger, and Tyson Foods.

BMO has announced the redemption of its MicroSectors™ FANG+™ Index 3× Leveraged ETNs (FNGA) and reminded investors about the availability of its replacement product, the FNGB ETNs.

The FNGA ETNs will be redeemed on May 15, 2025, with the last trading day expected to be May 14, 2025. BMO is exercising this call right due to increased costs associated with supporting the leverage, making current fees no longer reflective of market conditions.

The new FNGB ETNs, trading under ticker 'FNGB' since February 20, 2025, offers similar 3x leveraged exposure to the NYSE FANG+® Index. It features a discounted Daily Investor Fee of 0.35% per annum until August 19, 2025, after which it will increase to 0.95% per annum.

Bank of Montreal (BMO) held its Annual Meeting of Shareholders on April 11, 2025, where shareholders elected 13 directors to the company's board. The election results showed strong shareholder support, with all nominees receiving over 94% approval.

Notable results include Brian McManus receiving the highest approval rate at 99.69% of votes, while George A. Cope received the lowest but still strong support at 94.93%. The voting results demonstrated particularly strong confidence in several directors, including Stephen Dent (99.62%), David Harquail (99.61%), and Hazel Claxton (99.55%).

BMO is set to host its second annual Obesity Summit on March 25, 2025, in New York, focusing on the expanding $150 billion obesity therapies market. The summit will bring together healthcare industry experts and leaders to examine trends in metabolic disease and drug therapies.

The event features prominent companies including Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock, and Structure Therapeutics. Participants will explore advances in GLP-1 drug therapies with insights from pharmacy benefit managers, patients, and providers.

The summit's agenda includes fireside chats, expert panels, and presentations featuring BMO Sr. Biotechnology & Pharmaceuticals Analyst Evan Seigerman, FlyteHealth Co-Founder Dr. Katherine Saunders, and Dr. Louis J. Aronne, Sanford I. Weill Professor of Metabolic Research. Key topics include care delivery, emerging technologies, coverage and access, and patient insights on GLP-1+ therapy.